#ASH24: Aggressive B-cell NHL

To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to aggressive B-cell non-Hodgkin lymphoma (NHL), here.  

CONGRESS | #ASH24 | PRESENTATION
Jean-Marie Michot, Gustave Roussy Institute of Cancer discussed 2-year follow-up data from part 2 of the CC-99282-NHL-001 trial of golcadomide plus rituximab (R) in patients with R/R DLBCL.
Golcadomide + R demonstrated a predictable and manageable… pic.twitter.com/oTpUS5nVNz

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | PRESENTATION@DrMatasar @RutgersCancer @RWJBarnabas shared data from the phase I ELM-1 trial of odronextamab monotherapy in patients with R/R DLBCL progressing after CAR T-cell therapy.
Odronextamab showed promising efficacy, with an ORR of 48%, CR rate of… pic.twitter.com/xk9EiG4CmA

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS #ASH24 | PRESENTATION@DrMatasar, Rutgers Cancer Institute discussed data from a phase II trial of glofitamab in R/R LBCL. Safety profile was consistent with previous analysis. 77.2% of pts with CR at EOT were alive after 24 months, with evidence of immune recovery 12-18… pic.twitter.com/MHCUT57iQd

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | PRESENTATION
Franck Morschhauser @univ_lille shared initial efficacy and safety data from the phase II EPCORE DLBCL-3 trial of fixed-duration epcoritamab monotherapy in older (≥75 yr), anthracycline-ineligible patients with previously untreated LBCL.
With… pic.twitter.com/rHtSVW2I64

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Julio C. Chavez, @MoffittNews shared results from a phase II trial of mosunetuzumab + polatuzumab (mosun-pola) vs rituximab + polatuzumab (R-Pola) in patients with R/R LBCL.
Fixed-duration mosun-pola showed improved efficacy vs R-Pola, with an… pic.twitter.com/XaKKYlmWpf

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION@DocHutchings, University of Copenhagen shared extended follow-up data from the phase Ib/II trial of glofitamab + polatuzumab in patients with R/R LBCL including HGBCL. After a median follow-up of 28.2 months, glofitamab + polatuzumab continued to… pic.twitter.com/LNVptV5uuH

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS #ASH24 | PRESENTATION@Lymphoma_Doc, @MDAndersonNews discussed the CC-220-DLBCL-001 trial of GOLCA + R-CHOP efficacy in a-BCL. At EOT, 80% of high risk genomic patients were MRD negative with GOLCA 0.4mg, vs 17% with GOLCA 0.2mg. 1-yr PFS was 85% with 0.4mg GOLCA.… pic.twitter.com/Ww6lQ9rPIZ

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@gilles_salles @MSKCancerCenter presents results from a 5-year analysis of the POLARIX trial.
5-year year follow-up results demonstrate a sustained and significant PFS and DFS benefit for patients treated with Pola-R-CHP vs R-CHOP. Safety profiles… pic.twitter.com/7Yxx7hUMxb

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS #ASH24 | PRESENTATION
Catherine Diefenbach, @Perlmutter_CC discussed the final analysis of the phase Ib BO42203 trial of ventoclax combination with Pola-R-CHP for BCL-2 IHC+ DLBCL. No new safety signals were observed; all pts had at least 1 AE. The EOT PET-CT based ORR… pic.twitter.com/jDqi3xbWK0

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@araujo_ferran of Institut D’Investigacions Biomèdiques August Pi I Sunyer discussed the prognosis potential of CD70 and its biological role in patients with FL and development of a novel dual CD19-CD70 CAR T-cell therapy for FL and B-NHL.
Follow… pic.twitter.com/S1xb1lk3Wu

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Lorenzo Falchi @MSKCancerCenter shared 2- year follow-up data from the Arm 2 of the EPCORE NHL-2 trial of epcoritamab + rituximab + lenalidomide in R/R FL. Fixed-duration epcoritamab + rituximab + lenalidomide continued to show deep and durable… pic.twitter.com/8gHqyQjfDf

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Simone Ferrero at University of Torino presented data from the MRD-driven phase III FOLL12 trial comparing conventional rituximab maintenance (after R-CHOP or BR) vs a combined PET/MRD response-adapted post-induction approach in FL. MRD monitoring… pic.twitter.com/G7pB5oHTmQ

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@AshAlizadeh @StanfordCancer presents results from an analysis of ctDNA MRD in the liso-cel and SOC arms of the phase III TRANSFORM trial.
Achieving MRD-negativity was associated with improved EFS in both treatment arms. Among patients who… pic.twitter.com/d2dEo9y6xS

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
Nirav Shah @niravshahmd @mcw_oncology presents interim results from the phase II DALY II USA study.
Zamto-cel demonstrated encouraging efficacy, with an ORR of 72.8%, and there were low incidences of CRS and ICANS in patients with R/R DLBCL.… pic.twitter.com/uPpBIPYd8d

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
Peter Riedell, @UChicagoMed shares results from an interim analysis of a phase II trial of rapcabtagene autoleucel in patients with R/R DLBCL.
Rapcabtagene autoleucel showed promising efficacy and a tolerable safety profile, with an ORR of 88.3%.… pic.twitter.com/Voudr868JR

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Evgenii Shumilov, University Hospital Muenster discussed timing of CAR-T failure as a predictor for outcome with BsAbs therapy in r/r LBCL. Highest response rate was observed in pts with late CAR-T failure. Efficacy of BsAb is significantly impaired… pic.twitter.com/Ha9WbR8yAF

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Taylor Brooks, @ClevelandClinic presented results from the REALBiTE study of patients receiving epco or glofit. The ORR was 53%, with no sig difference between the BsAbs in response. Median OS was 7.9 months. In this heavily-pretreated population,… pic.twitter.com/FBH4yvThEI

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Jean-Nicolas Champagne, BC Cancer Vancouver discussed a study in 53 pts recieving R-CHOP-like therapy for late relapse DLBCL. 72% of pts achieved CR/PR. 2-y TTP was 55%, Median OS 39 months. R-CHOP-like therapy provided best reponses in pts with… pic.twitter.com/jKZsvsvgEn

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
David Wald @cwru shares results from a phase I trial of UF-Kure19, an ultra-fast CAR T-cell manufacturing platform, in patients with R/R NHL.
UF-Kure19 demonstrated durable response rates and was well tolerated in patients with NHL.
Follow our… pic.twitter.com/uCL9arDkQF

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | POSTER | John N. Allan @WeillCornell presents a pooled analysis from ELM-1 and ELM-2 of the long-term safety and efficacy data for odronextamab in R/R DLBCL. These data support the durable efficacy and manageable safety profile, with low-grade CRS events and… pic.twitter.com/gSLSA92M5J

— Lymphoma Hub (@lymphomahub) December 13, 2024

CONGRESS | #ASH24 | POSTER
Varun Iyengar, @MSKCancerCenter shared real-world data of 1L polatuzumab and impact of frailty in older adults with newly diagnosed DLBCL.
Real-world response rated to 1L polatuzumab containing regimens were consistent with those reported in the… pic.twitter.com/3WfHvR9uBE

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER
Lori A. Leslie @JTCancerCenter shared long-term data from Arm 8 of the EPCORE NHL-2 trial of fixed-duration epcoritamab + R-Mini-CHOP in patients with previously untreated DLBCL.
Epcoritamab + R-mini-CHOP treatment continues to demonstrate encouraging… pic.twitter.com/3lPydwE9aO

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER@nancybartlettMD, @SitemanCenter, discussed safety and efficacy outcomes from the ECHELON-3 trial (NCT04404283) evaluating brentuximab vedotin + lenalidomide + rituximab (BV+Len+R) in a subset of patients with R/R DLBCL aged ≥65 years (n=155) and ≥75… pic.twitter.com/X9l5HSkmzJ

— Lymphoma Hub (@lymphomahub) December 11, 2024